The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy

被引:7
作者
Eitan, Ram
Soslow, Robert
Lin, Oscar
Kauff, Noah D.
Liu, Lisa
Barakat, Richard R.
Chi, Dennis S.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA
[2] Shaare Zedek Med Ctr, Dept Obstet & Gynecol, Jerusalem, Israel
[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
risk-reducing salpingo-oophorectomy; mesothelial atypia; BRCA1; BRCA2; peritoneal washings; breast cancer; ovarian cancer;
D O I
10.1016/j.ygyno.2005.12.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Occult cancer may be found in a small proportion of women undergoing risk-reducing salpingo-oophorectorny (RRSO). However, the results and significance of peritorical wash cytology in this setting are not clear. The objective of this study was to determine the significance of cytologic mesothelial atypia in the peritoneal washings of patients undergoing RRSO. Methods. We conducted a retrospective chart review of all patients undergoing RRSO from July 2002 to December 2003. Patient charts were reviewed for information regarding cytology, pathology, demographics, surgical procedure and findings, and outcome. Results. One hundred thirty women underwent RRSO during the study period. One hundred seventeen had washings performed during the procedure and constitute the study cohort. The median age at the time of the procedure was 48 years (range, 33-78 years). Final cytology was reported as normal in 102 patients (87%), mesothelial atypia in 13 (11%), and non-satisfactory in 2 (2%). Ovarian and tubal histopathology,vas normal in all cases. No association was found between mesothelial atypia and age, prior breast cancer, or prior abdominal surgery. Twenty-nine patients had previously undergone genetic testing for BRCA1/2 mutations as part of ongoing prospective follow-up studies. Four (24%) of 17 patients with a known BRCA1 or BRCA2 mutation were found to have mesothelial atypia compared to 1(8%) of 12 with no mutation. With a median follow-up time of 20 months (range, 1-40 months), none of the patients with mesothelial atypia were diagnosed with peritoneal malignancy following RRSO. Conclusion. In this study, mesothelial atypia was identified in 11% of patients who had peritoneal washings performed at the time of RRSO. No patients with mesothelial atypia went on to develop peritoneal carcinoma. The link between mesothelial atypia and mutations in BRCA1/2 and the need to perforin peritoneal washings in this setting are both yet to be determined. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:315 / 318
页数:4
相关论文
共 17 条
[11]   Modifiers of risk of hereditary breast and ovarian cancer [J].
Narod, SA .
NATURE REVIEWS CANCER, 2002, 2 (02) :113-+
[12]   Risk-reducing salpingo-oophorectomy in BRCA mutation carriers:: Role of serial sectioning in the detection of occult malignancy [J].
Powell, CB ;
Kenley, E ;
Chen, LM ;
Crawford, B ;
McLennan, J ;
Zaloudek, C ;
Komaromy, M ;
Beattie, M ;
Ziegler, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :127-132
[13]   Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations [J].
Rebbeck, TR ;
Lynch, HT ;
Neuhausen, SL ;
Narod, SA ;
van't Veer, L ;
Garber, JE ;
Evans, G ;
Isaacs, C ;
Daly, MB ;
Matloff, E ;
Olopade, OI ;
Weber, BL .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) :1616-1622
[14]   Systematic review of management options for women with a hereditary predisposition to ovarian cancer [J].
Rosen, B ;
Kwon, J ;
Fung, MFK ;
Gagliardi, A ;
Chambers, A .
GYNECOLOGIC ONCOLOGY, 2004, 93 (02) :280-286
[15]  
Satagopan JM, 2002, CLIN CANCER RES, V8, P3776
[16]   Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers [J].
Scheuer, L ;
Kauff, N ;
Robson, M ;
Kelly, B ;
Barakat, R ;
Satagopan, J ;
Ellis, N ;
Hensley, M ;
Boyd, J ;
Borgen, P ;
Norton, L ;
Offit, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1260-1268
[17]   The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [J].
Struewing, JP ;
Hartge, P ;
Wacholder, S ;
Baker, SM ;
Berlin, M ;
McAdams, M ;
Timmerman, MM ;
Brody, LC ;
Tucker, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) :1401-1408